<DOC>
	<DOCNO>NCT00110721</DOCNO>
	<brief_summary>This Phase II , multi-center study GM-CT-01 show increase anti-tumor activity 5-fluorouracil ( 5-FU ) mouse . 5-FU chemotherapy drug commonly use cancer patient . In Phase II study , patient colon cancer spread , despite treatment approve therapy , receive GM-CT-01 plus 5-FU monthly cycle least 2 cycle disease progress .</brief_summary>
	<brief_title>GM-CT-01 Plus 5-Fluorouracil Third- Fourth-Line Therapy Metastatic Colorectal Cancer</brief_title>
	<detailed_description>A Phase I study 40 patient show GM-CT-01 different dos plus 5-FU well tolerated patient different type solid tumor fail standard , approved treatment . The main reason Phase II study advance colorectal cancer patient verify safety observation early Phase I study evaluate efficacy drug ' combination stabilize tumor , prevent growth potentially shrink tumor .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>18 year age older Has histologicallyproven adenocarcinoma colon rectum Has documentation locally advance metastatic colorectal cancer amenable curative surgery radiotherapy Eligible subject whose unresectable , locally advanced and/or metastatic colorectal cancer progress receive treatment least two , three , line therapy collectively must include minimum follow agent : 5fluorouracil capecitabine , irinotecan , oxaliplatin ( unless , opinion investigator , subject able receive irinotecan and/or oxaliplatin due medical contraindication , case irinotecan and/or oxaliplatin require include prior line therapy ) . Adjuvant chemotherapy follow definitive management primary lesion colon rectum allow counted line therapy . Has 1 measurable lesion ( ) ( `` target lesion [ ] '' ) accord RECIST ( Response Evaluation Criteria Solid Tumors ) criterion . The diagnostic imaging method must use throughout study evaluate lesion ; clinically detect lesion consider measurable superficial ( e.g. , skin nodule palpable lymph node ) . Has ECOG performance status 02 Has life expectancy great 3 month Has ability understand nature study hazard participate ; communicate satisfactorily Investigator ; participate , comply , requirement entire study A female childbearing potential must negative serum screen test pregnancy agree practice abstinence use effective method contraception Has aspects protocol explain write informed consent obtain Has central nervous system metastasis Has bony metastasis sole metastasis Has concomitant previous malignancy past 3 year , except : adequately treat situ carcinoma uterine cervix ; basal squamous cell carcinoma skin ; and/or melanoma situ . Is receive concomitant antineoplastic treatment ; receive radiation therapy past 3 week ; treat antiangiogenesis agent , include bevacizumab , past 4 week ; treat chemotherapeutic agent past 4 week ( 6 week mitomycin C nitrosoureas ) . Has active infection Has congestive heart failure ( Class III IV New York Heart Association functional classification system ) Has hemoglobin level &lt; 8.5 gm/dL Has platelet count &lt; 100,000/mm3 Has neutrophil count &lt; 1,500/mm3 Has serum creatinine level &gt; 2.0 mg/dL Has liver aminotransferase alkaline phosphatase level &gt; 2.5 time laboratory 's upper limit normal ( ULN ) subject liver metastasis , level &gt; 5 time laboratory 's ULN subject liver metastases Has total bilirubin level &gt; 2 time laboratory 's ULN Has pulmonary DLCO &lt; 60 % predict Has know clinically suspected infection human immunodeficiency virus ( HIV ) Has participate within 30 day , participate concurrently , another investigational drug vaccine study Has history drug alcohol dependence past 3 year Has serious , nonmalignant , significant , acute chronic medical psychiatric illness , judgment Investigator , could compromise subject safety , limit subject 's ability complete study , and/or compromise objective study Has know intolerance 5 FU Has previously participate GMCT01 clinical trial Has know hypersensitivity GMCT01 component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>DAVANAT</keyword>
	<keyword>5-fluorouracil</keyword>
</DOC>